Navigation Links
Liquid biomaterials take stem cell therapy to new level
Date:3/17/2011

At present, cartilage implants created using stem cells can only be constructed as a solid shape, acting as an interim measure before the almost inevitable need for total joint replacement.

Now researchers at the University of Bristol are investigating the possibilities of a biologically-engineered synthetic liquid polymer that would eliminate the need for further surgery by offering a one stop, permanent solution.

Dr Wael Kafienah, from Bristol's School of Medical Sciences, believes this research could represent the next breakthrough in stem cell therapy. He and his team are collaborating with researchers in Canada and Qatar to explore how such a biomaterial could be created. Dr Kafienah, the lead Principal Investigator for Bristol, has been funded by the Qatar National Research Fund (QNRP), with approximately $1 million over a period of three years to conduct the initial research. The QNRP has an international annual cycle of highly competitive, peer-reviewed, collaborative funding.

If the research proves successful, clinical trials could be carried out within five years.

Initial research shows that an injectable gel would have the capacity to form three-dimensional scaffolds that could be moulded to assume the solid form of even an irregularly shaped defected area, resulting in the formation of new tissue that would fully fill the defect at the point of delivery and encourage the growth of healthy cells.

A gel-based biomaterial could also be used for immunotherapy, where stem cells injected into the body would stimulate the immune system to destroy the tumour by providing a source of gene therapies or therapeutic vaccines. Injecting these stem cells in the form of a gel would allow clinicians to target the tumour through a prolonged, controlled release of the therapeutic proteins required, with obvious benefits to the patient as there would be fewer courses of treatment.

Dr Kafienah said: "The versatility of injectable polymers and stem cells opens up endless opportunities for cell-based therapies. For instance, the polymer-cell constructs can be used to create cartilage implants that can grow at the defect site without the need for the expensive process of growing the tissue in the lab before hand. The technology can also aid bone fracture repair where the presence of stem cells is shown to enhance bone repair capacity but require a flexible vehicle to sustain their delivery. There is a rapidly expanding area of regenerative medicine that is hugely dependent on injectable biomaterials. The novel biomaterials we are working on would be ideal for this, given what we anticipate to be their superior mechanical properties and cell guiding chemistry."

The research builds on the advances already made by Bristol's team of stem cell and tissue engineering experts in creating cartilage from adult human bone marrow stem cells, coupled with the work of researchers at Memorial University of Newfoundland in Canada and Qatar University in creating novel injectable biomaterials for cartilage tissue engineering.


'/>"/>

Contact: Aliya Mughal
aliya.mughal@bristol.ac.uk
44-117-331-7033
University of Bristol
Source:Eurekalert

Related medicine news :

1. A new high-resolution method for imaging below the skin using a liquid lens
2. Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid
3. Announcing NutriVite, Liquid Multivitamin Shots - Welcome to the Future of Vitamins
4. GMP Labs Expands Liquid Nutraceutical Capabilities
5. New Liquid Functional Nutrition Products: EYL Beverages Announces Debut of DeCOMPRESS™ and Debug™ Beverages at Natural Products EXPO West
6. Liquid Love: Last Minute Valentines Day Gift For Your Heart
7. New therapy found for rare lung disorder
8. Sirolimus therapy alleviates symptoms of lung disease LAM
9. Research study explores gene therapy treatment to reduce symptoms of Parkinsons disease
10. University Hospitals Case Medical Center testing innovative heat therapy for premature ejaculation
11. Ohio State study: Targeted ovarian cancer therapy not cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... who administered fillers that resulted in severe facial disfiguration. After four frightening years ... by doctors at UCLA Medical Center, who removed the substances in a partial ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full service ... in the California Bay Area, is launching a charity drive to raise awareness of ... disease is the primary killer of adult men and women in America, and is ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative ... Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries from ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... analysis instruments and consumables for the medical and veterinary ... its financial results for the third quarter fiscal year ... at 4:15 p.m. ET on Thursday, January 26, 2017.  ... quarter fiscal year 2017 after the market closes on ...
(Date:1/19/2017)... Massachusetts , January 19, 2017 ... ) announced that the U.S. Food and Drug Administration ... of a New Drug Application (NDA) for SHP465, a ... evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder ... on or around June 20, 2017, the designated Prescription ...
Breaking Medicine Technology: